Technical Analysis for RAPT - RAPT Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 31.3 0.51% 0.16
RAPT closed up 0.51 percent on Wednesday, February 19, 2020, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Up
Historical RAPT trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Oversold Stochastic Weakness 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.51%
Narrow Range Bar Range Contraction 0.51%
Wide Bands Range Expansion 0.51%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


RAPT Therapeutics, Inc., a clinical stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company develops small molecules that are designed to modulate the critical immune responses underlying these diseases. Its lead oncology drug candidate is FLX475 for the treatment of a range of tumors; and RPT193, a CCR4 antagonist for allergic inflammatory disease. The company is also pursuing a range of targets, including general control nonderepressible and hematopoietic progenitor kinase for the treatment of cancer. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
Biotechnology Biopharmaceutical Cancer Life Sciences Pharmaceutical Industry Diseases Treatment Of Cancer Pharmacy Tumors Specialty Drugs Inflammatory Diseases Bristol Myers Squibb Small Molecule Therapies

Is RAPT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 51.2095
52 Week Low 11.85
Average Volume 94,848
200-Day Moving Average 0.00
50-Day Moving Average 32.71
20-Day Moving Average 37.87
10-Day Moving Average 31.10
Average True Range 3.53
ADX 25.71
+DI 21.14
-DI 21.69
Chandelier Exit (Long, 3 ATRs ) 40.63
Chandelier Exit (Short, 3 ATRs ) 38.44
Upper Bollinger Band 51.80
Lower Bollinger Band 23.93
Percent B (%b) 0.26
BandWidth 73.59
MACD Line -1.33
MACD Signal Line 0.01
MACD Histogram -1.3471
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 33.04
Resistance 3 (R3) 33.01 32.40 32.75
Resistance 2 (R2) 32.40 31.96 32.42 32.65
Resistance 1 (R1) 31.85 31.68 32.13 31.88 32.56
Pivot Point 31.24 31.24 31.38 31.26 31.24
Support 1 (S1) 30.69 30.80 30.97 30.72 30.04
Support 2 (S2) 30.08 30.52 30.10 29.95
Support 3 (S3) 29.53 30.08 29.85
Support 4 (S4) 29.56